Four people died and at least 11 others have gotten sick from a rare flesheating bacteria found in warm coastal waters. Of the dozens of species of the bacteria, it's vibrio vulnificus that has health officials worried as infections can be severe and life-threatening for some. It can spread from raw seafood, mainly oysters, or through an open wound in direct contact with seawater.Anyone can get this infection and sometimes it can be pretty mild, but um it can spread pretty rapidly. Doctors recommend coverin ...

Tonight, chaos after a car plows into a crowd in Los Angeles. At least 30 people hurt, seven critically as police say a man intentionally rammed this car into a crowd outside a Hollywood nightclub. That crowd fighting back, the driver shot as dramatic video shows bystanders dragging him from the vehicle.And just in, we've learned he was kicked out of the club before it all happened. The storm system threatening millions. Tornado sirens blaring in Iowa as dangerous waters rise from Illinois to Virginia.Where ...

Tonight, a warning from Florida health officials after four people died and at least 11 others have gotten sick from a rare flesh-eating bacteria found in warm coastal waters. Of the dozens of species of the bacteria, it's vibrio vulonicus that has health officials worried as infections can be severe and life-threatening for some. It can spread from raw seafood, mainly oysters, or through an open wound in direct contact with seawater.Bernie Stewart contracted the bacteria 6 years ago. The charter boat capta ...

As awareness of the microbiome has grown, the shelves of health-food shops have become stocked with products designed to boost good bacteria. But which ones actually work? https://t.co/ohrzwRnQc4 ...

Beach Closures & Public Health Concerns - At least five states, including New York, California, Massachusetts, Michigan, Illinois, and Washington State, are tracking beach closures due to rising bacteria levels in the water [1] - Health officials are urging people not to enter the water at 17 beaches in the Chicago area [1] Bacteria & Infection Risks - There isn't one common cause across all regions; Washington State is dealing with toxic algae, while other areas are concerned about E coli [2] - Vibrio, a bacteria naturally occurring in coastal waters, is a concern due to potential spikes during extreme heat and heavy rain [2] - Infection can occur if swimmers swallow contaminated water or if water enters open wounds [2]

The H. pylori bacteria, linked to ulcers and stomach cancer, may also slow the growth of an abnormal protein tied to Alzheimer’s, @fayeflam says (via @opinion) https://t.co/PxJbOuOKTZ ...

Gut-Brain Axis & Mental Health - The gut-brain axis enables direct influence from the gut on the brain, affecting physical and emotional states [3] - Gut bacteria produce approximately 90% of the body's serotonin, a key hormone for happiness and emotional stability [4] - Gut bacteria imbalance, known as dysbiosis, can lead to anxiety, depression, and cognitive decline [5] Impact of Diet & Lifestyle - Poor diet, stress, and antibiotics can cause gut bacteria imbalance [4] - Foods like yogurt, sauerkraut, kimchi, and kefir are excellent sources of probiotics, restoring gut balance and supporting mental health [6] - Exercise encourages beneficial bacteria growth and increases intestinal mobility, benefiting both body and mind [6][7] - Diets high in sugar and processed foods can lead to gut bacteria imbalance [8][9] - Stress management and adequate sleep are vital for maintaining healthy gut bacteria and overall well-being [7][8] Probiotics & Prebiotics - Prebiotics, found in foods like bananas, onions, garlic, and asparagus, feed beneficial gut bacteria [5][6] - Probiotic supplements may enhance mood and lessen anxiety, but using the correct strains is crucial [10]

Core Insights - The market for bacterial vaginosis (BV) treatments in the U.S. is projected to reach $1.0 billion by 2033, driven by increasing incidence, public health awareness, and improved diagnostics [3][4]. Company Overview - Evofem Biosciences, Inc. is focused on women's sexual and reproductive health, with two FDA-approved products generating revenue [8]. - The company relaunched SOLOSEC in November 2024 and is promoting it alongside PHEXXI to OB/GYNs in the U.S. [9]. - Evofem is entering global markets through strategic partnerships, including a license agreement for launching products in the UAE in 2026 [9]. Product Development - SOLOSEC (secnidazole) is being studied for its efficacy in managing recurrent BV, with a recent study showing that once-weekly dosing may match or exceed the effectiveness of current CDC-recommended treatments [2][3]. - The study involved 24 women and indicated that the once-weekly dosing could improve adherence compared to more complex treatment regimens [3][5]. - SOLOSEC is currently approved for treating BV in women aged 12 and older, but its use for recurrent BV is still investigational [5][7]. Market Dynamics - BV affects approximately 21 million women in the U.S., with up to 50% experiencing recurrence within six months of treatment [4][6]. - The high recurrence rate of BV presents a significant burden on patients and the healthcare system, highlighting the need for more effective treatment options [4][6]. Strategic Initiatives - Evofem has entered into a definitive agreement to be acquired by Aditxt, Inc., aiming to enhance its focus on women's health innovations [10].

MannKind Jefferies Global Healthcare Conference June 5, 2025 © Copyright 2025. All rights reserved. MannKind Corporation. Cautionary Statement Statements in this presentation that are not statements of historical fact are forward- looking statements that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward- looking statements are based upon ...

Core Viewpoint - Spero Therapeutics is focused on advancing its tebipenem HBr clinical program, which aims to provide an oral carbapenem option for complicated urinary tract infections, with an interim analysis of the ongoing Phase 3 PIVOT-PO trial expected in Q2 2025 [2][7][8]. Financial Results - For Q1 2025, Spero reported a net loss of $13.9 million, compared to a net loss of $12.7 million in Q1 2024, resulting in a diluted net loss per share of $0.25 versus $0.24 in the prior year [9][18]. - Total revenue for Q1 2025 was $5.9 million, down from $9.3 million in Q1 2024, primarily due to a decrease in grant revenue, although collaboration revenue increased [9][10]. - Research and development expenses decreased to $13.6 million in Q1 2025 from $17.3 million in Q1 2024, mainly due to lower spending on the SPR720 clinical program [15]. - General and administrative expenses rose to $6.8 million in Q1 2025 from $5.9 million in Q1 2024, attributed to higher personnel-related costs and consulting fees [15]. - As of March 31, 2025, Spero had cash and cash equivalents of $48.9 million, which, along with expected milestone payments from GSK, is projected to fund operations into Q2 2026 [15]. Pipeline Update - Tebipenem HBr is being developed for the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis (AP), with the goal of reducing inpatient therapy duration [3][8]. - The oral development program for NTM-PD was suspended in Q4 2024 after an interim analysis indicated it did not meet its primary endpoint [8]. Corporate Update - Esther Rajavelu was appointed as President and CEO of Spero effective May 2, 2025, and has been nominated for election to the Board of Directors [5].